Filter Results:
(20)
Show Results For
- All HBS Web (20)
- Faculty Publications (9)
Show Results For
- All HBS Web (20)
- Faculty Publications (9)
Page 1 of 20
Results
- February 2014
- Case
GSK Sets the Stage for Sustainability in Singapore
By: Vicki L. Sato, Rich Ballenger, Sen Chai, Ross Leimberg and Mariana Mihalusova
- November 2013 (Revised September 2015)
- Supplement
GlaxoSmithKline in China (B)
By: John A. Quelch and Margaret L. Rodriguez
In 2013, Chinese investigators detained four GSK employees for allegedly bribing health care staff to sell GSK pharmaceuticals. A month later, GSK's Asia Pacific regional president, Abbas Hussain, said the company would help identify corrupt practices. Two days later,... View Details
Keywords: Public Health; Pharmaceuticals; China; Bribery; CSR; Hong Bao; Health Care; Drug; GlaxoSmithKline; GSK; Witty; Government; Marketing; Health; Health Care and Treatment; Corporate Social Responsibility and Impact; Corporate Strategy; Corporate Governance; Business and Government Relations; Ethics; Pharmaceutical Industry; China; United Kingdom; United States
Quelch, John A., and Margaret L. Rodriguez. "GlaxoSmithKline in China (B)." Harvard Business School Supplement 514-050, November 2013. (Revised September 2015.)
- March 2014 (Revised December 2014)
- Case
Vision 2020: Takeda and the Vaccine Business
By: John A. Quelch and Margaret L. Rodriguez
In 2014, Yasuchika Hasegawa was orchestrating the transformation of Takeda from a Japanese pharmaceutical company with a global footprint into a global company with a Japanese heritage. A 33-year veteran of Takeda, Hasegawa-san was appointed president of Takeda in 2003... View Details
Keywords: Health Care; Global; NGO; Public Health; Japan; GSK; Vaccine; Supply Chain; Market Entry; Health; Health Care and Treatment; Trade; Market Entry and Exit; Global Strategy; Health Industry; Pharmaceutical Industry
Quelch, John A., and Margaret L. Rodriguez. "Vision 2020: Takeda and the Vaccine Business." Harvard Business School Case 514-084, March 2014. (Revised December 2014.)
- November 2013
- Case
GlaxoSmithKline in China (A)
By: John A. Quelch and Margaret L. Rodriguez
Four GlaxoSmithKline employees were accused of bribing Chinese health care workers to prescribe the company's drugs. The accusations brought to light the questionable incentive structures of the Chinese health care system and the pressure on companies to adhere to... View Details
Keywords: Public Health; Pharmaceuticals; China; Bribery; CSR; Hong Bao; Health Care; Drug; GlaxoSmithKline; GSK; Witty; Government; Marketing; Health; Health Care and Treatment; Corporate Social Responsibility and Impact; Corporate Strategy; Corporate Governance; Business and Government Relations; Ethics; Pharmaceutical Industry; China; United Kingdom; United States
Quelch, John A., and Margaret L. Rodriguez. "GlaxoSmithKline in China (A)." Harvard Business School Case 514-049, November 2013.
- April 2009
- Case
GSK's Acquisition of Sirtris: Independence or Integration?
By: Toby E. Stuart and James Weber
An executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's global head of R&D, championed the acquisition of Sirtris to gain access to its potentially revolutionary science.... View Details
Keywords: Mergers and Acquisitions; Resource Allocation; Organizational Change and Adaptation; Organizational Culture; Organizational Structure; Research and Development; Science-Based Business; Integration
Stuart, Toby E., and James Weber. "GSK's Acquisition of Sirtris: Independence or Integration?" Harvard Business School Case 809-026, April 2009.
- October 2012
- Case
GSK's Acquisition of Sirtris: Independence or Integration? (Abridged)
By: Toby Stuart and James Weber
An executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's global head of R&D, championed the acquisition of Sirtris to gain access to its potentially revolutionary science.... View Details
Keywords: Mergers and Acquisitions; Resource Allocation; Organizational Change and Adaptation; Organizational Culture; Organizational Structure; Research and Development; Science-Based Business; Integration
Stuart, Toby, and James Weber. "GSK's Acquisition of Sirtris: Independence or Integration? (Abridged)." Harvard Business School Case 813-028, October 2012.
- June 2012
- Case
GlaxoSmithKline in Brazil: Public-Private Vaccine Partnerships
By: Arthur A. Daemmrich and Ian McKown Cornell
Three years into a major public-private partnership between GlaxoSmithKline and Fiocuz, Brazil's principal health institute, the company assesses technology transfer and joint research under the agreement. GSK was selling its Synflorix vaccine (against pediatric... View Details
Keywords: Public-Private Partnerships; Business and Government Relations; Foreign Direct Investment; Health Care and Treatment; Globalized Firms and Management; Biotechnology Industry; Pharmaceutical Industry; Brazil
Daemmrich, Arthur A., and Ian McKown Cornell. "GlaxoSmithKline in Brazil: Public-Private Vaccine Partnerships." Harvard Business School Case 712-049, June 2012.
- September 2013 (Revised February 2016)
- Case
GlaxoSmithKline: Sourcing Complex Professional Services
By: Heidi K. Gardner and Silvia Hodges Silverstein
Pharmaceutical company GlaxoSmithKline (GSK) uses an innovative new approach to procuring outside legal counsel: it replaces relationship-based selection and law firms' traditional time-based billing with data-driven decision making and an online reverse auction. In... View Details
Keywords: Legal Industry; Procurement; Professional Service Firms; Pricing; Competition; Change Management; Supply Chain Management; Legal Liability; Business Processes; Legal Services Industry; Pharmaceutical Industry
Gardner, Heidi K., and Silvia Hodges Silverstein. "GlaxoSmithKline: Sourcing Complex Professional Services." Harvard Business School Case 414-003, September 2013. (Revised February 2016.)
- May 2005 (Revised April 2010)
- Case
GlaxoSmithKline: Reorganizing Drug Discovery (A)
By: Robert S. Huckman and Eli Strick
Describes the reorganization of drug discovery at GlaxoSmithKline (GSK) following the formation of GSK from the merger of Glaxo Wellcome and SmithKline Beecham. This reorganization placed nearly 2,000 research scientists into six centers of excellence in drug discovery... View Details
Keywords: Mergers and Acquisitions; Decision Choices and Conditions; Operations; Organizational Structure; Performance Improvement; Research and Development; Pharmaceutical Industry
Huckman, Robert S., and Eli Strick. "GlaxoSmithKline: Reorganizing Drug Discovery (A)." Harvard Business School Case 605-074, May 2005. (Revised April 2010.)
- Fast Answer
Bloomberg: tickers
How do I type tickers in Bloomberg? Examples: MSFT US [EQUITY] for Microsoft Corp. stock VOD LN [EQUITY] for Vodafone stock GSK 5.375 04/15/34 [CORP] for GlaxsoSmithKline bond Bloomberg tickers include the following: ticker (e.g.,... View Details
- 01 Jun 2002
- News
Late Start, Dramatic Finish
bold new strategy for dealing with the HIV/AIDS epidemic in Africa,” team member Lyn Baranowski wrote in the Harbus. Noting that the case encompassed ethics and leadership issues as well as marketing challenges, she added, “When the GSK... View Details
Rudina Seseri
the Business School and is an HBS inaugural group member of Rock Venture Capital Partners. She is also a Member of the Business Leadership Council of Wellesley College and an Advisor for GSK Consumer. Previously, Rudina has served as... View Details
Keywords: Software/App;#75;#Venture Capital
- 10 Sep 2008
- Research & Ideas
Long-Tail Economics? Give Me Blockbusters!
result in dead ends but occasionally lead in an unexpected direction to a blockbuster result. Some big budget movies are flops, others are sleepers, still others meet expectations. More risky than pursuing blockbusters is not to pursue them. Perhaps the CEO of View Details
- 12 Nov 2013
- First Look
First Look: November 12
reverse auction. In the case, GSK is hit with a potentially devastating suit and must hire a firm in time to respond. The recently hired managing attorney, Sophia Keating, grapples with GSK's approach. The View Details
Keywords: Sean Silverthorne
- 12 May 2009
- First Look
First Look: May 12, 2009
Case 809-026 An executive from pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's global head of R&D, championed the acquisition of Sirtris to gain access... View Details
Keywords: Martha Lagace
- 19 Sep 2012
- Research & Ideas
Funding Innovation: Is Your Firm Doing it Wrong?
programs to an investment board comprising both insiders (senior GSK executives) and outsiders (including a venture capitalist and a biotech CEO). After a three-month review period, successful teams are awarded three years worth of... View Details
Keywords: by Carmen Nobel
- 18 Dec 2012
- First Look
First Look: December 18
pharmaceutical company GSK must choose how much to integrate a recently acquired biotechnology firm, Sirtris. Moncef Slaoui, GSK's global head of R&D, championed the acquisition of Sirtris to gain access to its potentially... View Details
Keywords: Carmen Nobel
- 07 Aug 2012
- First Look
First Look: August 7
health institute, the company assesses technology transfer and joint research under the agreement. GSK was selling its Synflorix vaccine (against pediatric pneumonia) at fixed prices even as it transferred technology and know-how to... View Details
Keywords: Sean Silverthorne
- 06 May 2014
- First Look
First Look: May 6
Purchase this case: http://hbr.org/product/glaxosmithkline-in-china-a/an/514049-PDF-ENG Harvard Business School Case 514-050 GlaxoSmithKline in China (B) In 2013, Chinese investigators detained four GlaxoSmithKline (GSK) employees for allegedly bribing health care... View Details
Keywords: Sean Silverthorne
- 22 Jul 2008
- First Look
First Look: July 22, 2008
minds—the deep metaphors that reveal people's true feelings about products. The solution: Find ways to generate positive emotional associations, as GSK has done with its weight-loss product. Alex Lee, president of household-products maker... View Details
Keywords: Martha Lagace